<DOC>
	<DOCNO>NCT00329940</DOCNO>
	<brief_summary>The purpose study assess rheumatologic tolerability letrozole postmenopausal patient hormone receptor positive breast cancer discontinue anastrozole adjuvant treatment due musculoskeletal disorder .</brief_summary>
	<brief_title>Safety Rheumatologic Tolerability Letrozole Postmenopausal Patients With Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal woman receive anastrozole adjuvant therapy hormone receptor positive breast cancer want interrupt treatment severe rheumatologic adverse event Polymorphonuclear neutrophil ( PNN ) ≥ 1200/mm3 , platelet ≥ 100000/mm3 , hemoglobin ( Hb ) ≥ 10 g/dL Bilirubin ≤ 30 μmol , SGOT/SGPT &lt; 3N Fully sign informed consent Pain due bone fracture Metastatic disease Hormone therapy anastrozole Incapacitating uncontrolled concomitant disease could hamper patient 's quality life Hypersensitivity letrozole component Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Letrozole</keyword>
	<keyword>breast cancer</keyword>
	<keyword>critical musculoskeletal</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>rheumatologic tolerance</keyword>
</DOC>